Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Oct. 25 to 29, 2021. This […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Oct. 25 to 29, 2021. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
FDA Approves Pfizer COVID-19 Vaccine for Children Aged 5 to 11
FRIDAY, Oct. 29, 2021 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved the emergency use of a smaller dose of the Pfizer COVID-19 vaccine for children ages 5 to 11 years, paving the way for 28 million children across the country to get their shots.
Health Officials Say U.S. COVID-19 Cases Fell 60 Percent Since September
FRIDAY, Oct. 29, 2021 (HealthDay News) — COVID-19 cases have plunged by 60 percent since mid-September’s delta-driven peak, U.S. health officials said earlier this week. But with winter on the way, they warned that Americans still need to protect themselves and others against the virus.
For Fully Vaccinated, Immunity Against SARS-CoV-2 Wanes Over Time
FRIDAY, Oct. 29, 2021 (HealthDay News) — In all age groups, immunity against the delta variant of severe acute respiratory syndrome coronavirus 2 decreased a few months after receipt of the second dose of the BNT162b2 vaccine, according to a study published online Oct. 27 in the New England Journal of Medicine.
Cognitive Dysfunction Fairly Common After COVID-19 Infection
FRIDAY, Oct. 29, 2021 (HealthDay News) — A substantial proportion of relatively young COVID-19 survivors exhibit cognitive dysfunction several months after recovering from COVID-19, according to a research letter published online Oct. 22 in JAMA Network Open.
Higher Dose of Steroid Does Not Improve Outcomes in Severe COVID-19
FRIDAY, Oct. 29, 2021 (HealthDay News) — The number of days alive without life support at day 28 did not differ among adults with COVID-19 and severe hypoxemia receiving dexamethasone 12 mg/day versus dexamethasone 6 mg/day administered intravenously for up to 10 days, according to a study published online Oct. 21 in the Journal of the American Medical Association.
Clinically Active IBD Linked to Adverse COVID-19 Outcomes
FRIDAY, Oct. 29, 2021 (HealthDay News) — Clinically active inflammatory bowel disease is associated with adverse COVID-19 outcomes, especially in younger and middle-aged adults, according to a study published online Sept. 27 in the Journal of Crohn’s and Colitis.
Nearly 59,000 Meatpacking Workers Caught COVID-19
THURSDAY, Oct. 28, 2021 (HealthDay News) — The number of U.S. meatpacking workers who were infected during the COVID-19 pandemic is nearly three times higher than previously thought, a U.S. House report shows.
COVID-19 Vaccination Not Linked to First-Trimester Miscarriage
Trends Reported in Vaccination Coverage for Adolescents for 2025 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
Social Media Warnings Could Discourage Use Among Teens, Young Adults 
Digital Behavioral Health Game Reduces Depressive Symptoms in Teens .jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
Reinitiating Obesity Meds After Bariatric Surgery Tied to Greater One-Year Weight Loss in Youths 
.jpeg)
